Beckman Coulter Diagnostics appoints Catherine Jennings as President
Beckman Coulter Diagnostics, a Danaher company, has appointed Catherine “Cat” Jennings as President. In the role, Jennings will lead the company’s strategic, operational and organisational priorities, applying a culture of continuous improve-ment to accelerate innovation, strengthen global impact and help laboratories and clinicians deliver better patient outcomes.
Healthcare leadership background
Jennings brings more than 20 years of healthcare industry leadership experience. She joins from Boston Scientific, where she most recently served as President of Vascular Therapies, leading a global business of approximately $2 billion (about €1.76 billion) in annual revenue. She holds a Bachelor of Science in Biology from Georgetown University and a Master of Business Administration from the University of California, Los Angeles.
Kevin O’Reilly, Group Executive, Danaher Diagnostics, said: “Cat is an accomplished healthcare leader with a strong track record of driving growth, fostering innovation and developing high-performing teams. As part of Danaher’s connected diagnostics ecosystem, Beckman Coulter Diagnostics brings together deep expertise, global scale and customer partnership to address some of healthcare’s toughest challenges. Cat’s leadership will help us accelerate innovation and expand the impact of diagnostic solutions around the world.”
Jennings said: “It is an honour to join Beckman Coulter Diagnostics, a company with a remarkable legacy of innovation and a mission deeply aligned with my passion for improving patient outcomes. Diagnostics play a critical role in helping clinicians make informed decisions. I look forward to collaborating closely with customers, healthcare providers and partners around the world to solve some of the most demanding problems in diagnostics and help bring meaningful innovation to patients faster.”
Catherine Jennings has been appointed President of Beckman Coulter Diagnostics
Scale of the business
Jennings takes over a company with a broad reach. More than one million tests per hour are run on Beckman Coulter Diagnostics laboratory systems worldwide, affecting approximately 1.2 billion patients and more than three million clinicians annually. The company, which has worked in diagnostics for more than 90 years, is headquartered in Brea, California, and has more than 10,000 team members. Jennings will lead it as it continues to expand diagnostic insights that help laboratories, healthcare providers and health systems deliver better patient outcomes.